News for Allogene Therapeutics, Inc. (ALLO)

Transaction Overview On February 28, 2025, FMR LLC (Trades, Portfolio) executed a significant transaction involving Allogene Therapeutics Inc (ALLO), a biotechn

**media[555577]**

On February 25, 2025, Pfizer Inc (Trades, Portfolio), a leading entity in the investment landscape, executed a noteworthy transaction involving Haleon PLC. The

Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases. Read why I'm bullish on ALLO stock.

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. ( ALLO), a clinical-stage biotechnology company pioneering the deve

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. ( ALLO), a clinical-stage biotechnology company pioneering the deve

**media[550247]**

Allogene Therapeutics is undervalued. Read more on ALLO stock's cash runway, innovative CAR-T therapies, and market expansion with potential breakthroughs.

On February 18, 2025, Deborah Messemer, a Director at Allogene Therapeutics Inc (ALLO), sold 13,313 shares of the company. Following this transaction, the insid

U.S. stocks were lower, with the Dow Jones falling around 100 points on Tuesday. Shares of Watsco Inc WSO rose sharply during Tuesday's session after the compa...

On December 31, 2024, Lynx1 Capital Management LP (Trades, Portfolio) made a significant move by acquiring an additional 4,672,349 shares of Allogene Therapeuti

Transaction Overview On December 31, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving Allogene Therapeutics Inc (ALLO), a clinical

**media[527277,527278]**

Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Allogene Therapeutics, Inc. (ALLO) experienced a significant stock decline of 5.14%, with the price at $2.03 per share. The trading volume reached 1.08186 milli

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. ( ALLO), a clinical-stage biotechnology company pioneering the deve

On December 9, 2024, Deborah Messemer, a Director at Allogene Therapeutics Inc (ALLO), sold 9,136 shares of the company. Following this transaction, the insider

Allogene Therapeutics has demonstrated encouraging early results in lymphoma, moving aggressively into a pivotal trial in the first-line setting. Read more here.

Allogene Therapeutics, Inc. (ALLO) experienced a significant stock increase of 5.02%, reaching $2.30 per share with a trading volume of 1.319 million shares. Th